Jose Cervera

List of Publications by Year
in descending order

138 papers	5,141 citations	136950 32 h-index	102487 66 g-index
142 all docs	142 docs citations	142 times ranked	5612 citing authors

#	Article	IF	Citations
1	New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. Journal of Clinical Oncology, 2012, 30, 820-829.	1.6	584
2	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	30.7	372
3	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
4	Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood, 2013, 121, 3005-3015.	1.4	251
5	Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood, 2016, 128, 1408-1417.	1.4	249
6	Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica, 2011, 96, 375-383.	3.5	226
7	Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. Blood, 2001, 98, 2332-2338.	1.4	220
8	Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica, 2005, 90, 1168-78.	3.5	163
9	The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Human Molecular Genetics, 2002, 11, 1391-1397.	2.9	139
10	Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica, 2003, 88, 19-24.	3.5	135
11	Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica, 2004, 89, 926-33.	3.5	97
12	Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression. Leukemia Research, 2006, 30, 1471-1491.	0.8	94
13	Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica, 2010, 95, 424-431.	3.5	84
14	Assessing an Improved Protocol for Plasma microRNA Extraction. PLoS ONE, 2013, 8, e82753.	2.5	81
15	Lack of RPS14 promoter aberrant methylation supports the haploinsufficiency model for the 5q- syndrome. Blood, 2008, 112, 918-918.	1.4	78
16	Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene. Cancers, 2020, 12, 624.	3.7	77
17	The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. Haematologica, 2007, 92, 308-314.	3.5	76
18	Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. British Journal of Haematology, 2007, 136, 590-596.	2.5	75

#	Article	IF	Citations
19	Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood, 2008, 112, 3383-3390.	1.4	74
20	Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. British Journal of Haematology, 2013, 162, 74-86.	2.5	73
21	DNA Methylation Profiles and Their Relationship with Cytogenetic Status in Adult Acute Myeloid Leukemia. PLoS ONE, 2010, 5, e12197.	2.5	73
22	A novel NUP98/RARG gene fusion in acute myeloid leukemia resembling acute promyelocytic leukemia. Blood, 2011, 117, 242-245.	1.4	65
23	Correlation Between Preoperative Magnetic Resonance Imaging and Surgical Margins with Modified Mohs for Dermatofibrosarcoma Protuberans. Dermatologic Surgery, 2011, 37, 1638-1645.	0.8	53
24	EVI1is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements. Genes Chromosomes and Cancer, 2006, 45, 349-356.	2.8	51
25	A comprehensive strategy for the subtyping of patients with Fanconi anaemia: conclusions from the Spanish Fanconi Anemia Research Network. Journal of Medical Genetics, 2007, 44, 241-249.	3.2	47
26	Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia. Haematologica, 2011, 96, 1448-1456.	3.5	45
27	Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing. Genes Chromosomes and Cancer, 2013, 52, 1167-1177.	2.8	44
28	Epigenetic regulation of the nonâ€canonical Wnt pathway in acute myeloid leukemia. Cancer Science, 2010, 101, 425-432.	3.9	43
29	Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. Cancer, 2012, 118, 127-133.	4.1	43
30	FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies. Leukemia Research, 2002, 26, 725-730.	0.8	41
31	The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia. Leukemia Research, 2007, 31, 947-953.	0.8	40
32	Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes. Oncotarget, 2017, 8, 106948-106961.	1.8	38
33	Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-. Haematologica, 2008, 93, 1001-1008.	3.5	36
34	Adverse prognostic value of MYBL2 overexpression and association with microRNA-30 family in acute myeloid leukemia patients. Leukemia Research, 2013, 37, 1690-1696.	0.8	36
35	Impact ofABCsingle nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. Leukemia and Lymphoma, 2017, 58, 1197-1206.	1.3	33
36	Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): Comparison with WT1 gene expression. Clinica Chimica Acta, 2008, 395, 120-123.	1.1	32

#	Article	IF	Citations
37	Radioprotective activity and cytogenetic effect of resveratrol in human lymphocytes: An in vitro evaluation. Food and Chemical Toxicology, 2013, 51, 391-395.	3.6	32
38	CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. Haematologica, 2011, 96, 1557-1559.	3.5	31
39	Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies. Haematologica, 2009, 94, 827-832.	3.5	29
40	Assessment inÂvitro of radioprotective efficacy of curcumin and resveratrol. Radiation Measurements, 2011, 46, 962-966.	1.4	29
41	Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations. Oncotarget, 2016, 7, 80916-80924.	1.8	29
42	Graft-versus-tumour effect in non-small-cell lung cancer after allogeneic peripheral blood stem cell transplantation. SHORT REPORT. British Journal of Haematology, 2000, 111, 708-710.	2.5	29
43	CRISPR to fix bad blood: a new tool in basic and clinical hematology. Haematologica, 2019, 104, 881-893.	3.5	26
44	Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes. British Journal of Haematology, 2012, 159, 311-321.	2.5	25
45	Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia. British Journal of Haematology, 2020, 188, 605-622.	2.5	25
46	Rapid Detection of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia Using High-Resolution Melting Analysis. Journal of Molecular Diagnostics, 2009, 11, 458-463.	2.8	24
47	Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with riskâ€adapted protocols. Cancer, 2014, 120, 3958-3964.	4.1	24
48	Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics. Journal of Molecular Diagnostics, 2019, 21, 228-240.	2.8	24
49	The Mutational Landscape of Acute Promyelocytic Leukemia Reveals an Interacting Network of Co-Occurrences and Recurrent Mutations. PLoS ONE, 2016, 11, e0148346.	2.5	23
50	SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor. British Journal of Haematology, 2005, 129, 791-794.	2.5	22
51	Immunofluorescent analysis with the anti-PML monoclonal antibody PG-M3 for rapid and accurate genetic diagnosis of acute promyelocytic leukemia. Annals of Hematology, 2004, 83, 687-690.	1.8	21
52	In vitro all-trans retinoic acid sensitivity of acute myeloid leukemia blasts with NUP98/RARG fusion gene. Annals of Hematology, 2014, 93, 1931-1933.	1.8	21
53	CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia. Haematologica, 2015, 100, e183-e185.	3.5	20
54	In vitro cytogenetic and genotoxic effects of curcumin on human peripheral blood lymphocytes. Food and Chemical Toxicology, 2012, 50, 3229-3233.	3.6	19

#	Article	IF	Citations
55	Identification of two atypical PMLâ€“RARÎ± transcripts in two patients with acute promyelocytic leukemia. Leukemia Research, 2002, 26, 439-442.	0.8	18
56	Impact of <scp>SNP</scp> array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases. American Journal of Hematology, 2016, 91, 185-192.	4.1	18
57	MLL amplification in acute myeloid leukemia. Cancer Genetics and Cytogenetics, 2007, 174, 127-131.	1.0	17
58	Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia. Leukemia Research, 2012, 36, 174-181.	0.8	17
59	TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes. Blood, 2019, 134, 675-675.	1.4	17
60	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nature Communications, 2021, 12, 6233.	12.8	17
61	Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: Does â^'7/7qâ^' detection by FISH have prognostic value?. Leukemia Research, 2013, 37, 416-421.	0.8	16
62	Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis. Annals of Hematology, 2019, 98, 2081-2088.	1.8	16
63	Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: Review of 5,654 patients with an evaluable karyotype. Genes Chromosomes and Cancer, 2013, 52, 753-763.	2.8	15
64	Liver disease as primary manifestation of multiple myeloma in a young man. Leukemia Research, 1999, 23, 403-405.	0.8	14
65	Negative impact on clinical outcome of the mutational co-occurrence ofSF3B1andDNMT3Ain refractory anemia with ring sideroblasts (RARS). Leukemia and Lymphoma, 2017, 58, 1686-1693.	1.3	14
66	Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7. Leukemia, 2020, 34, 2441-2450.	7.2	14
67	Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia. Annals of Hematology, 2012, 91, 1-7.	1.8	13
68	Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemia. Leukemia Research, 2001, 25, 685-692.	0.8	12
69	Rapid Screening of ASXL1, IDH1, IDH2, and c-CBL Mutations in de Novo Acute Myeloid Leukemia by High-Resolution Melting. Journal of Molecular Diagnostics, 2012, 14, 594-601.	2.8	12
70	Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment. Leukemia and Lymphoma, 2017, 58, 2880-2894.	1.3	12
71	Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy. Leukemia and Lymphoma, 2019, 60, 1146-1155.	1.3	12
72	Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea. Leukemia, 2021, 35, 623-627.	7.2	12

#	Article	IF	Citations
73	Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome. Leukemia Research, 2011, 35, 834-836.	0.8	11
74	Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome. Leukemia Research, 2013, 37, 769-776.	0.8	11
75	WT1 isoform expression pattern in acute myeloid leukemia. Leukemia Research, 2013, 37, 1744-1749.	0.8	11
76	Correlation of myelodysplastic syndromes with i(17)(q10) and <scp>TP</scp>53 and <scp>SETBP</scp>1 mutations. British Journal of Haematology, 2015, 171, 137-141.	2.5	11
77	Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts. Blood Cancer Journal, 2017, 7, 630.	6.2	11
78	Adverse prognostic impact of complex karyotype (â‰¥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). Leukemia Research, 2021, 109, 106612.	0.8	11
79	Study of the S427G polymorphism and ofMYBL2variants in patients with acute myeloid leukemia. Leukemia and Lymphoma, 2016, 57, 429-435.	1.3	10
80	Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 659-668.	1.3	10
81	Somatic Genetic and Epigenetic Architecture of Myelodysplastic Syndromes Arising from GATA2 Deficiency. Blood, 2015, 126, 299-299.	1.4	10
82	A t(17;20)(q21;q12) masking a variant t(15;17)(q22;q21) in a patient with acute promyelocytic leukemia. Cancer Genetics and Cytogenetics, 2006, 168, 73-76.	1.0	9
83	High-level amplification of the RUNX1 gene in two cases of childhood acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 2006, 170, 171-174.	1.0	9
84	Aberrant methylation of tumor suppressor genes in patients with refractory anemia with ring sideroblasts. Leukemia Research, 2011, 35, 479-483.	0.8	9
85	Sister chromatid exchange, (SCE), High-Frequency Cells (HFCs) and SCE distribution patterns in peripheral blood lymphocytes of Spanish adult smokers compared to non-smokers. Food and Chemical Toxicology, 2014, 66, 107-112.	3.6	9
86	Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group. Leukemia Research, 2017, 63, 85-89.	0.8	9
87	Clonal genetic evolution at relapse of favorable-risk acute myeloid leukemia with NPM1 mutation is associated with phenotypic changes and worse outcomes. Haematologica, 2018, 103, e400-e403.	3.5	9
88	Analysis of SNP rs16754 of WT1 gene in a series of de novo acute myeloid leukemia patients. Annals of Hematology, 2012, 91, 1845-1853.	1.8	8
89	Novel Real-Time Polymerase Chain Reaction Assay for Simultaneous Detection of Recurrent Fusion Genes in Acute Myeloid Leukemia. Journal of Molecular Diagnostics, 2013, 15, 678-686.	2.8	8
90	Clinical and molecular characterization by next generation sequencing of Spanish patients affected by congenital deficiencies of fibrinogen. Thrombosis Research, 2019, 180, 115-117.	1.7	8

#	Article	IF	Citations
91	Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype. Scientific Reports, 2020, 10, 5904.	3.3	8
92	Locked Nucleic Acid-Enhanced Detection of 1100delC*CHEK2 Germ-Line Mutation in Spanish Patients with Hematologic Malignancies. Clinical Chemistry, 2004, 50, 2201-2204.	3.2	7
93	Single-Nucleotide Polymorphism Array-Based Karyotyping of Acute Promyelocytic Leukemia. PLoS ONE, 2014, 9, e100245.	2.5	7
94	Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes. Genes Chromosomes and Cancer, 2016, 55, 322-327.	2.8	7
95	Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. Leukemia and Lymphoma, 2017, 58, 145-152.	1.3	7
96	GuÃa prÃ¡ctica de tratamiento urgente de la microangiopatÃa trombÃ³tica. Medicina ClÃnica, 2018, 151, 123.e1-123.e9.	0.6	7
97	Measurement of Creatinine in Whole Blood Samples Supplemented to Achieve Increased Creatinine Concentrations. Clinical Chemistry, 2008, 54, 451-452.	3.2	6
98	RNA Sequencing Analysis for the Identification of a PCM1/PDGFRB Fusion Gene Responsive to Imatinib. Acta Haematologica, 2019, 142, 92-97.	1.4	6
99	Somatic Mutations of ASXL1, RUNX1 and SETBP1 Improve Prognostic Stratification of Patients with Chronic Myelomonocytic Leukemia. Blood, 2014, 124, 1915-1915.	1.4	6
100	Prognostic value of cytogenetics in adult patients with Philadelphia-negative acute lymphoblastic leukemia. Annals of Hematology, 2012, 91, 19-25.	1.8	5
101	The modular network structure of the mutational landscape of Acute Myeloid Leukemia. PLoS ONE, 2018, 13, e0202926.	2.5	5
102	A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms. Cancers, 2021, 13, 1947.	3.7	5
103	Aberrant Alternative Splicing in U2af1/Tet2 Double Mutant Mice Contributes to Major Hematological Phenotypes. International Journal of Molecular Sciences, 2021, 22, 6963.	4.1	5
104	Additional Chromosome Abnormalities Have No Prognostic Value in Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Anthracycline-Based Chemotherapy: An Update of the APL96 and APL99 Pethema Protocols.. Blood, 2004, 104, 2019-2019.	1.4	5
105	Screening forIDHmutations in chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2013, 54, 406-407.	1.3	4
106	BRAFV600E mutation in adult acute lymphoblastic leukemia. Leukemia and Lymphoma, 2013, 54, 1105-1106.	1.3	4
107	Factor XIII deficiency in two Spanish families with a novel variant in gene F13A1 detected by next-generation sequencing; symptoms and clinical management. Journal of Thrombosis and Thrombolysis, 2020, 50, 686-688.	2.1	4
108	A new reliable fluorescencein situhybridization method for identifying multiple specific cytogenetic abnormalities in acute myeloid leukemia. Leukemia and Lymphoma, 2010, 51, 680-685.	1.3	3

#	Article	IF	Citations
109	Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance. Genes Chromosomes and Cancer, 2018, 57, 547-556.	2.8	3
110	Could ATRA/Idarubicin treatment of acute promyelocytic leukemia induce the appearance of new clonal cytogenetic abnormalities in patients in complete remission?. Leukemia Research, 2007, 31, 1315-1317.	0.8	2
111	Frequency of dicentrics and contamination levels in Ukrainian children and adolescents from areas near Chernobyl 20 years after the nuclear plant accident. International Journal of Radiation Biology, 2013, 89, 944-949.	1.8	2
112	Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation. Annals of Hematology, 2019, 98, 2151-2162.	1.8	2
113	Gene Microdeletions in Adult and Pediatric Acute Lymphoblastic Leukemia,. Blood, 2011, 118, 3539-3539.	1.4	2
114	New Chemistry Cartridge for the GEM Premier 4000 Critical Care Analyzer, Including Electrochemical Sensors for Creatinine, Urea, and Measured Bicarbonate. Point of Care, 2010, 9, 1-7.	0.4	1
115	Analysis of the Possible Persistent Genotoxic Damage in Workers Linked to the Ardystil Syndrome. Genetic Testing and Molecular Biomarkers, 2016, 20, 94-97.	0.7	1
116	Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia. Journal of Personalized Medicine, 2020, 10, 244.	2.5	1
117	Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain. European Journal of Haematology, 2021, 106, 724-733.	2.2	1
118	Prognostic Impact of Anthracycline Metabolism Gene Polymorphisms in Newly Diagnosed Acute Myeloid Leukemia Adults. Blood, 2014, 124, 2237-2237.	1.4	1
119	Impact of Transporter Genes Polymorphisms in Standard Induction of Acute Myeloid Leukemia. Blood, 2015, 126, 4842-4842.	1.4	1
120	Influence of Single Nucleotide Polymorphisms in Anthracycline Metabolism Pathway in Standard Induction of Acute Myeloid Leukemia. Blood, 2015, 126, 4845-4845.	1.4	1
121	1: Analysis of Risk Factors in Adults Transplanted with UCB for Treatment of Hematologic Malignancy. Biology of Blood and Marrow Transplantation, 2007, 13, 1393.	2.0	0
122	Absence of mutations in the activation loop and juxtamembrane domains of VEGFR-1 and VEGFR-2 gene in chronic myelomonocytic leukemia (CMML). Leukemia Research, 2012, 36, e50-e51.	0.8	0
123	Long-Term Outcome and Prognostic Factors after Single-Unit Umbilical Cord-Blood Transplantation (UCBT) for Adults with Hematologic Malignancies.. Blood, 2006, 108, 3129-3129.	1.4	0
124	The JAK2 V617F Mutation Identifies Specific Subgroups of Myelodysplastic Syndrome (MDS).. Blood, 2006, 108, 2610-2610.	1.4	0
125	Incidence and Characteristics of Acute Promyelocytic Leukemia in Adult Patients. A Single Centre Registry Study.. Blood, 2007, 110, 4301-4301.	1.4	0
126	Loss of the Y Chromosome in MDS - Age-Related Phenomenon or Clonal Abnormality?. Blood, 2010, 116, 4008-4008.	1.4	0

#	Article	IF	Citations
127	Quantitative Expression Analysis of WT1 Main Isoforms in AML. Blood, 2011, 118, 1469-1469.	1.4	0
128	Analysis of ASXL1, IDH1, IDH2, c-CBL, and WT1 Mutations in De Novo Acute Myeloid Leukaemia. Blood, 2011, 118, 1450-1450.	1.4	0
129	Association of MDM2 Gene Polymorphisms SNP285 and 309 with Myelodysplastic Syndromes (MDS) Susceptibility and Outcome.. Blood, 2012, 120, 2823-2823.	1.4	0
130	Utility of SNP Arrays in Chronic Myelomonocytic Leukemia with Low Risk Cytogenetic Features or No Metaphases. Blood, 2014, 124, 4659-4659.	1.4	0
131	Genomic Microarray Alterations Add Prognostic Power to the IPSS-R in MDS with Normal Karyotype. Blood, 2014, 124, 3262-3262.	1.4	0
132	Prognostic Impact of Cytarabine Pathway Gene Polymorphisms in Acute Myeloid Leukemia Adults Undergoing Induction Chemotherapy. Blood, 2014, 124, 5223-5223.	1.4	0
133	Validation of a Next-Generation Sequencing Panel for AML Routine Diagnosis. Blood, 2015, 126, 1403-1403.	1.4	0
134	Simplified in-House Deep Sequencing Method of Inmunoglobulin Genes for Minimal Residual Dissease Quantification and Risk Stratification in Multiple Myeloma. Blood, 2015, 126, 2972-2972.	1.4	0
135	Comparison of the Molecular Spectrum of Lenalidomide-Treated Myelodysplastic Syndrome with and without Del(5q). Blood, 2016, 128, 3172-3172.	1.4	0
136	Clonal Hematopoiesis Landscape in Patients with De Novo Acute Myeloid Leukemia By Deep Sequencing. Blood, 2016, 128, 598-598.	1.4	0
137	Influence of Cytarabine Metabolic Pathway Polymorphisms in Acute Myeloid Leukemia Induction Treatment. Blood, 2016, 128, 5130-5130.	1.4	0
138	Germinal Predisposition in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction: Identification of Deleterious Variants in Microsatellite Instability Genes. Blood, 2019, 134, 4226-4226.	1.4	0